| abstract |
(57) [Summary]nThe present invention relates to a combination comprising a nonsteroidal anti-androgen and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for simultaneous, sequential or separate use in the synergistic treatment or prevention of prostate cancer. A therapeutic product. In particular, the products of the present invention are effective in inhibiting the conversion of prostate cancer cells from a hormone-dependent state to a hormone-independent state. Furthermore, the products of the present invention are expected to have a beneficial effect in preventing the development of prostate cancer in humans who are genetically susceptible to this disease. |